People · Operator
Named in public records as an officer, director or promoter · active 2008–2019 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Catabasis Pharmaceuticals Inc | — | Pharmaceuticals | Series D+ | $349.6M | $3.3B | 2013 |
| Portola Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $158.1M | $315.8M | 2008 |
| Aveo Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $98.2M | $263.2M | 2009 |
| Taligen Therapeutics Inc | — | Biotechnology | Series B | $62.1M | $1.4B | 2008 |
| Affymax Inc | — | Biotechnology | Series C | $42.0M | $1.7B | 2009 |
| Praxis Precision Medicines, Inc. | — | Pharmaceuticals | Series B | $31.9M | $340.0M | 2019 |
Nicholas Galakatos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nicholas Galakatos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Russell Hirsch | 2 | 10 |
| Nicholas C. Galakatos | 2 | 3 |
| David Johnson | 1 | 35 |
| Michael Ross | 1 | 18 |
| John Walker | 1 | 17 |
| James Topper | 1 | 12 |
| Ed Hurwitz | 1 | 9 |
| David Johnston | 1 | 8 |
| Robert Higgins | 1 | 7 |
| JEFF BIRD | 1 | 7 |
| Anthony Evnin | 1 | 6 |
| ABBIE CELNIKER | 1 | 6 |
| Jean George | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Douglas Cole | 1 | 5 |
| Alan Frazier | 1 | 5 |
| Thomas Dyrberg | 1 | 5 |
| Ted W. Love | 1 | 5 |
| Arlene Morris | 1 | 5 |
| WILLIAM D. YOUNG | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.